Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher (DHR) reported third-quarter 2026 revenue growth of 8.5% year over year, alongside higher earnings and increased full-year adjusted earnings guidance. Revenue reached $6.554 billion, while net earnings from continuing operations rose to $1.207 billion from $908 million. Diluted earnings per share from continuing operations were $1.71, versus $1.27. Non-GAAP adjusted diluted earnings per share increased 11.5% to $2.11.
Non-GAAP core revenue grew 3.0%, or 5.5% excluding respiratory revenue. Operating cash flow was $1.9 billion and non-GAAP free cash flow was $1.6 billion. Danaher raised its full-year adjusted diluted earnings guidance to $8.57–$8.62 per share, from $8.45–$8.60. For the fourth quarter, the company expects core revenue growth of approximately 3.0%, with growth excluding respiratory revenue of 4.0%–5.0%.
Danaher (DHR) announced a collaboration with NVIDIA to combine its scientific instruments and laboratory workflows with AI technologies. The companies are working to integrate AI into instruments, initially focusing on a select group of priority instruments, with potential expansion across the portfolio. Danaher aims to shorten the path from AI-generated predictions to experimental evidence, with experiments informing models and models helping design experiments.
Danaher (NYSE: DHR) appointed Daniel L. Comas and Robert Hershberg to its Board of Directors on October 9, 2026. Hershberg also joined the company's Science and Technology Committee. The board expanded from 11 to 13 directors to accommodate the appointments.
Alan G. Spoon will not stand for reelection at Danaher's 2027 Annual Meeting of Shareholders and will retire from the board at that time. The Nominating & Governance Committee continues to evaluate board composition through its regular governance and refreshment processes.
Danaher (DHR) announced plans to launch its first AI-powered autonomous lab to help researchers develop antibodies and other molecular tools. The lab, based at Abcam, is expected to operate at scale in early 2027. It will combine technologies from several Danaher businesses with robotic automation developed collaboratively with Automata. Designs will be built and tested, with results fed back into the AI model to improve subsequent designs.
Danaher (DHR) announced Julie Sawyer Montgomery has assumed the roles of President and Chief Executive Officer, effective October 1, 2026. She also joined the Board of Directors, following the succession announcement on August 3, 2026. Rainer Blair will serve as a senior advisor until March 31, 2027 to support the transition.
Danaher (DHR) will hold its third quarter 2026 earnings conference call on Wednesday, October 21, 2026, starting at 8:00 a.m. ET, with a duration of about one hour.
The live webcast, slide presentation, replay links and related earnings materials will be available in the Investors section of Danaher’s website. Investors can also join by phone using conference ID DHRQ326, with separate dial-in numbers for U.S. and international callers.
Danaher (DHR), through subsidiaries Integrated DNA Technologies (IDT) and Aldevron, launched co-developed research grade S.p. Cas9 mRNA in wild type and SpyFi™ high-fidelity formats for CRISPR-based genome editing workflows.
The offering combines IDT’s CRISPR engineering and guide RNA design expertise with Aldevron’s mRNA manufacturing capabilities, providing optimized constructs designed for high on-target editing, reduced off-target activity with SpyFi, low toxicity, and compatibility with multiple delivery methods including electroporation, cationic lipids, and lipid nanoparticles. The mRNA is enzymatically capped to offer a high-performing alternative to certain proprietary capping technologies and is positioned within a broader workflow that can progress from research grade to CGMP manufacturing, with additional co-developed base and prime editor products planned later.
Danaher (DHR)/b) declared a regular quarterly cash dividend of on its common stock. The dividend is payable on October 30, 2026 to shareholders of record as of the close of business on September 30, 2026.
Danaher (NYSE: DHR) appointed Julie Sawyer Montgomery as President, Chief Executive Officer, and Board member effective October 1, 2026, succeeding Rainer Blair, who will retire and serve as senior advisor until March 31, 2027 to support the leadership transition.
Since joining Danaher in 2017, Sawyer Montgomery has helped grow the Diagnostics platform from approximately $6.0 billion in revenue to about $11.0 billion, while approximately tripling operating profit. She led the acquisition of Masimo and the pending acquisition of StatLab and most recently served as Executive Vice President overseeing Diagnostics. Danaher also announced special equity incentive awards for key leaders and founders and confirmed there is no change to its previously communicated third-quarter and full-year 2026 guidance.
Danaher (NYSE: DHR) reported second quarter 2026 net earnings of $870 million, or $1.23 per diluted share, up 60% year-over-year. Non-GAAP adjusted diluted EPS rose 8% to $1.94. Revenue grew 5.5% to $6.3 billion, with non-GAAP core revenue up 3.0% and 4.5% excluding respiratory testing.
Operating cash flow was $1.5 billion and non-GAAP free cash flow $1.3 billion. Management cited a strong quarter in Life Sciences and mid-teens growth in bioprocessing orders, despite project timing effects on bioprocessing revenue. Danaher completed its Masimo acquisition earlier than anticipated and raised full-year 2026 adjusted EPS guidance to $8.45–$8.60, with expected non-GAAP core revenue growth of 3–4%.